Brazil's Anvisa approves five new semaglutide-based medications

Brazil's health regulator, Anvisa, has registered five new semaglutide medications, expanding the market for GLP-1 receptor agonists beyond the existing Ozempic and Wegovy brands. This move is expected to increase competition and potentially lower costs for patients, though the specific manufacturers and pricing strategies remain to be detailed.